Blinding Disease-Weight Loss Drug Link: EMA Announces Start of Semaglutide Investigation
Europe will scrutinize optic nerve ischemia risk among patients of drugs like Ozempic and Wegovy. The beginning of a high-stakes…
Outlook Therapeutics’ Bevacizumab Proves Non-inferior to Ranibizumab in 12-Week Trial
After failing to show non-inferiority to ranibizumab at 8 weeks late last year, ONS-5010’s new 12-week data strengthens the case…
latest posts
